AI summary · may contain errors
In a phase 3 trial in HABP/VABP patients, imipenem-cilastatin-funobactam showed 14-day all-cause mortality of 3.0% versus 2.7% for imipenem-cilastatin-relebactam.
- 1 cites
Moving in The Lancet Infectious Diseases, American Journal of Respiratory and Critical Care Medicine, Gastroenterology, Nature Communications and Clinical Infectious Diseases.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
In a phase 3 trial in HABP/VABP patients, imipenem-cilastatin-funobactam showed 14-day all-cause mortality of 3.0% versus 2.7% for imipenem-cilastatin-relebactam.
AI summary · may contain errors
A graded, revisable ICU-acquired pneumonia assessment framework links detected organisms to the plausibility of causing current lung injury, using reassessment at 48–72 hours.
AI summary · may contain errors
Enhanced oral care in three Australian hospitals is linked to lower non-ventilator hospital-acquired pneumonia incidence, with a cumulative hazard ratio of 0·40 (95% CI 0·19–0·82).
Journals this month
Topics moving, week to 17 Nov 2026
By field